According to this recent study, current findings, along with the previous discovery that the AXL/AKT axis mediates resistance to BRAF inhibition in melanoma with wild-type PTEN, provide new insights toward a strategy for combating BRAF inhibition-acquired resistance in BRAF mutant melanoma with different PTEN statuses.
This recent review addresses the clinical implications of the impact of germline melanocortin-1 receptor (MC1R) variants in melanoma and non-melanoma skin cancer risk, together with the additional risk conferred by somatic mutations in other peculiar genes, as well as the role of MC1R screening in skin cancer prevention.
According to this recent study, regular text messaging interventions result in significantly increased sun protection and decreased sunburn in young adults.
This review analyzes the complex interplay between nevi and melanoma predisposition in a familial context, distinguishing between nevi-related (cases with a high nevus count and a high polygenic risk score) and nevi-resistant (high/moderate-penetrance variant-carrier cases) familial melanoma. This distinction could better direct future research on genetic factors useful to identify high-risk subjects.
According to this recent study, there is evidence for cross-resistance between two unrelated therapies, and a scientific rationale for treating patients with immunotherapy before they acquire resistance to targeted therapy.
This recent study, describing the largest multicenter melanoma cohort investigated for Ataxia–Telangiectasia Mutated (ATM) germline variants, supports the role of ATM as a melanoma predisposition gene, with loss-of-function (LOF) variants suggesting a moderate-risk.
The purpose of this recent study was to examine associations with melanoma by anatomical site for a comprehensive set of risk factors including pigmentary and naevus phenotypes, ultraviolet radiation exposure and polygenic risk. The study found evidence of aetiological heterogeneity for melanoma, supporting the dual pathway hypothesis. These findings enhance understanding of risk factors for melanoma and can guide prevention and skin examination education and practices.
According to this recent study of multidisciplinary treatments, in this subgroup of cutaneous melanoma patients with BRAF wild-type status, locoregional metastases localized to inferior limbs and pelvis, in progression following or ineligible for immunotherapy, melphalan locoregional chemotherapy demonstrated a safe and effective profile.
According to this recent study, branched-chain amino acid transaminase 1 (BCAT1) knockdown suppressed melanoma cell proliferation and migration, which was associated with reduced oxidative phosphorylation. Data of the study indicate that BCAT1 is a promising therapeutic target for the treatment of malignant melanomas.
This study sought to determine whether regression in primary cutaneous melanomas predicted sentinel lymph node (SLN) status and survival outcomes in a large cohort of patients managed at a single centre. Findings indicate a prognostically favorable role of regression in primary cutaneous melanoma. However, in Stage III melanoma patients, regression may be a marker of more aggressive disease.